

Correction

Correction: MicroRNA-126 inhibits tumor proliferation and angiogenesis of hepatocellular carcinoma by down-regulating EGFL7 expression**Ming-Hua Hu¹, Chen-Yang Ma¹, Xiao-Ming Wang¹, Chen-Dong Ye², Guang-Xian Zhang¹, Lin Chen¹ and Jin-Guo Wang¹**¹Department of Surgery, Yijishan Hospital, Wannan Medical College, Wuhu 241001, P.R. China²Department of Surgery, The Second Affiliated Hospital, Wannan Medical College, Wuhu 241001, P.R. China*Published:* August 31, 2021**Copyright:** © 2021 Hu et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: The image in Figure 8, panel A is an accidental duplicate of the image in Figure 8, panel E. The corrected Figure 8, obtained using the original data, now shows the proper panel A. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2016; 7:66922–66934. <https://doi.org/10.18632/oncotarget.11877>




Figure 8: The VEGF-positive rate of transplanted tumors in nude mice among different groups detected by immunohistochemistry ($\times 200$). (A) The blank group; (B) The miR-126 mimics group; (C) The miR-126 inhibitors group; (D) The si-EGFL7 group; (E) The miR-126 inhibitors + si-EGFL7 group.